Chemotherapy in Treating Patients With Solid Tumors

NIAID Data Ecosystem2026-03-06 收录

实体瘤药物试验

I期临床试验

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2002684 数据链接链接失效反馈

官方服务：

资源简介：

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors that have not responded to previous therapy.

创建时间：

1997-08-15

Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib

肿瘤靶向治疗

I期临床试验

This is an open-label, phase 1, non-randomised, non-controlled trial, carried out in two centres on patients with advanced cancer expressing EGFR. Primary objective is the determination of the maximum

NIAID Data Ecosystem70

A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH

利什曼病疫苗

I期临床试验

Background Visceral leishmaniasis (VL or kala azar) is the most serious form of human leishmaniasis, responsible for over 20,000 deaths annually, and post kala azar dermal leishmaniasis (PKDL) is a st

NIAID Data Ecosystem50

DataSheet_1_Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors.docx

靶向抗癌药物

I期临床试验

BackgroundCT053PTSA is a novel tyrosine kinase inhibitor that targets MET, AXL, VEGFR2, FLT3 and MERTK. Here, we present preclinical data about CT053PTSA, and we conducted the first-in-human (FIH) stu

NIAID Data Ecosystem30

Supplementary Material for: A Phase I Study to Evaluate the Safety and Pharmacokinetics of SHR0302 Base Ointment in Healthy Adult Volunteers

I期临床试验

局部外用制剂药代动力学

Introduction: SHR0302 is a highly selective JAK1 inhibitor. This study aims to investigate the safety, tolerability, and pharmacokinetics of single- and multiple-dose topical skin application of SHR03

NIAID Data Ecosystem50

Dataset from A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Repeat Dose, Ascending Cohort, Dose Escalation Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban and Its Major Metabolite in Healthy Women Volunteers Following Administration of Repeat Dosing of Epelsiban

I期临床试验

药代动力学与安全性评估

The current study is designed to assess the safety, tolerability and pharmacokinetics (PK) of additional repeat doses of epelsiban in healthy females, and will be the first dosing experience of repeat

NIAID Data Ecosystem30

Chemotherapy in Treating Patients With Solid Tumors

资源简介：

相关数据集